alexa T-cell Responsiveness To Myelin Sheath Proteins (MSP)-derived Peptides In Multiple Sclerosis Patients Of Different Disease Types For A Randomized, Double-blind T Cell Vaccination Clinical Trial | 9899
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Vaccines & Vaccination

Rivka Abulafia-Lapid
Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.018
Abstract
Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Aim: In order to test anti-MSP autoimmunity in MS patients, T-cell specific responsiveness to the myelin sheath protein (MSP)- derived peptides were tested. Accordingly, a tailor-made specific vaccine was prepared for patients. Methodology: Here we report a cohort study testing T-cells isolated from 92 MS patients of 3 different disease types. The T-cell responsiveness to nine synthetic peptides derived from the major immunogenic epitopes - MSP, MBP, MOG and PLP, were tested. The results of this prescreening study were used for enrollment eligibility and for tailor-made (each patient received his own responsive T-cell lines) vaccine preparation. Results and Suggestions: Of the 92 patients tested, 54 were RR-MS, 38 RP-MS, SP-MS; EDSS disease ranged from 1 to 7.0. Of the 54 RR-MS patients, 59% responded to at least one of the protein peptides; 28% responded to MBP, 40% to MOG and 42% to PLP. Of the 38 RP-MS, SP MS patients, 31% responded to at least one of the protein peptides with 18% to MBP, 21% to MOG and 23% to PLP. RR-MS patients? response to myelin proteins was significantly higher than that of the RP-MS group suggesting a higher level of autoimmune activity in RR-MS patients. It is apparent that MOG is highly relevant as a primary target antigen in MS in spite of its minute quantity in the brain (0.01%). As a result of the screening described above, 26 patients with progressive MS were enrolled in the study (mean age: 39+9.8years; mean EDSS: 4.4?1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP, were raised from the patients? peripheral blood, each patient according to the specific responsiveness data. The clinical outcome of the study was recently reported as ? T-cell vaccination befits relapsing progressive multiple sclerosis patients in a randomized, double blind Clinical trial ," PLoS ONE clinical trials 7 (12); 1-10, 2012. In addition, a correlation was done between the T-cell responsiveness and the HLA-genotype from each patient for future peptide vaccine design.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7